Patent application number | Description | Published |
20080298759 | OPTICAL FIBER AND OPTICAL WAVEGUIDE - An optical fiber includes a core region having a first refractive index and a cladding region having a second refractive index lower than the first refractive index on an outer circumference of the core region. The cladding region includes four holes formed to have a four-fold rotational symmetry with respect to a center axis around the core region in a longitudinal direction, such that a zero-dispersion wavelength is 900 nm to 1150 nm and a cutoff wavelength is equal to or shorter than 950 nm. | 12-04-2008 |
20100239217 | OPTICAL FIBER AND OPTICAL WAVEGUIDE - An optical fiber includes a core region having a first refractive index and a cladding region having a second refractive index lower than the first refractive index on an outer circumference of the core region. The cladding region includes four holes formed to have a four-fold rotational symmetry with respect to a center axis around the core region in a longitudinal direction, such that a zero-dispersion wavelength is 900 nm to 1150 nm and a cutoff wavelength is equal to or shorter than 950 nm. | 09-23-2010 |
20120301610 | METHOD OF PRODUCING GLASS PREFORM AND APPARATUS FOR PRODUCING THE SAME - A method of producing a glass preform by depositing silica powder that contains silica particles on a starting material includes a transferring step, a disaggregating step, and a depositing step. The transferring step includes transferring the silica powder. The disaggregating step includes disaggregating and dispersing agglomerates of the silica particles contained in the silica powder while being transferred in the transferring step. The depositing step includes depositing the silica powder, which is transferred and is obtained by disaggregating and dispersing the agglomerates of the silica particles, on the starting material. | 11-29-2012 |
20130336343 | OPTICAL FIBER, OPTICAL FIBER LASER AND OPTICAL FIBER AMPLIFIER, AND METHOD OF MANUFACTURING OPTICAL FIBER - An optical fiber has: a core made of silica glass in which a rare earth element and aluminum have been added; an inner cladding layer that is formed around the core, is made of silica glass in which at least any one of an alkali metal and an alkali earth metal has been added, and has a refractive index lower than a refractive index of the core; and an outer cladding layer that is formed around the inner cladding layer and has a refractive index lower than the refractive index of the inner cladding layer. | 12-19-2013 |
20140240819 | MULTI-CORE AMPLIFICATION OPTICAL FIBER AND MULTI-CORE OPTICAL FIBER AMPLIFIER - A multi-core amplification optical fiber includes a plurality of rare-earth-doped core portions and a cladding portion positioned at an outer periphery of the core portions and having refractive index lower than those of the core portions. When a doping concentration of the rare-earth of each of the core portions is 250 ppm to 2000 ppm, a relative refractive index difference of each of the core portions relative to the cladding portion is 0.5% to 2% at a wavelength of 1550 nm, and a core diameter of each of the core portions is 1 μm to 5 μm, a separation distance between each of the core portions and adjacent one of the core portions is set at equal to or larger than 30 μm and at equal to or smaller than 60 μm so that a light-crosstalk between the adjacent core portions is equal to or lower than −30 dB. | 08-28-2014 |
Patent application number | Description | Published |
20080227699 | Therapeutic Agent for Neurodegenerative Diseases - The present invention relates to a pharmaceutical composition for the treatment and/or prevention of a neurodegenerative disease, comprising the following polypeptide shown in any of (a) to (c): (a) a polypeptide comprising the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1); (b) a polypeptide comprising an amino acid sequence having a deletion, substitution, insertion, and/or addition of one or several amino acids in the amino acid sequence consisting of Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala-Pro-Ala-Gly-Ala-Ser-Arg-Leu-Leu-Leu-Leu-Thr-Gly-Glu-Ile-Asp-Leu-Pro (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death associated with neurodegenerative disease; and (c) a modified polypeptide from the polypeptide (a) or (b), or a pharmaceutically acceptable salt thereof, as an effective ingredient. | 09-18-2008 |
20090075900 | Therapeutic agent for motor neuron disease - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b). | 03-19-2009 |
20100223684 | HUMANIN RECEPTOR OR HUMANIN-LIKE POLYPEPTIDE RECEPTOR - One aspect of the present invention is directed to search receptors based on the information of HN signaling pathways in order to find Humanin receptor or Humanin-like polypeptide receptor (HNR), and to reveal a mechanism of promoting or suppressing the intracellular signal transduction for neuroprotecting activity of HN and identify a compound involved in the mechanism. The aspect of the invention is directed to a method for screening of HNR agonist and HNR antagonist, to utilize the screened compound in development of a drug for the treatment of neurodegenerative disease, and to provide an assay system of AD neuronal cell death, and to provide methods for the compulsory expression of HNR gene or knocking-out of intracellular genes. | 09-02-2010 |
20100279942 | METHODS FOR TREATING MOTOR NEURON DISEASE - An object of the present invention is to provide an agent effective for the treatment and/or prevention of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The present invention provides a therapeutic and/or preventive agent for motor neuron disease comprising the following oligopeptide shown in any of (a) to (c) or a pharmaceutically acceptable salt thereof as an active ingredient: (a) an oligopeptide consisting of the amino acid sequence represented by Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1); (b) an oligopeptide consisting of an amino acid sequence having a deletion, substitution, insertion, or addition of one or several amino acids in Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO: 1), and having an activity that inhibits neuronal cell death caused by a mutant superoxide dismutase-1 gene; and (c) a modified oligopeptide from the oligopeptide (a) or (b). | 11-04-2010 |
20110250214 | DRUG DELIVERY SYSTEM TOWARD DEMYELINATING LESION AND BIOCHEMICAL MARKER OF DEMYELINATING LESION - It is intended to provide a drug delivery system toward a demyelinating lesion. It is also intended to provide a biochemical marker of a demyelinating lesion. A delivery system for a prophylactic and/or therapeutic agent for a demyelinating disease characterized in that a substance capable of specifically recognizing Contactin is conjugated to an active ingredient of a prophylactic and/or therapeutic agent for a demyelinating disease is provided. Also provided is a method of evaluating and/or differentiating a demyelinating disease, including measuring the expression of Contactin in a body fluid. | 10-13-2011 |
Patent application number | Description | Published |
20110002807 | STEEL FOR INDUCTION HARDENING - This steel for induction hardening includes: in terms of mass %, C: 0.40% or more to 0.75% or less; Si: 0.002% or more to 3.0% or less; Mn: 0.20% or more to 2.0% or less; S: 0.002% or more to 0.1% or less; Al: more than 0.10% to 3.0% or less; P: 0.030% or less; and N: 0.035% or less, with the remainder being Fe and inevitable impurities. | 01-06-2011 |
20110239835 | STEEL FOR MACHINE STRUCTURE USE EXCELLENT IN CUTTING TOOL LIFETIME AND MACHINING METHOD OF SAME - Steel for machine structure use excellent in tool lifetime in a broad range of cutting speeds regardless of continuous machining, intermittent machining, or other systems and further in various machining environments such as use of a cutting fluid or a dry, semidry, and oxygen enriched environment, having a chemical composition containing, by mass %, C: 0.01 to 1.2%, Si: 0.005 to 3.0%, Mn: 0.05 to 3.0%, P: 0.0001 to 0.2%, S: 0.0001 to 0.35%, N: 0.0005 to 0.035%, and Al: 0.05 to 1.0%, satisfying [Al %]−(27/14)×[N %]≧0.05%, and having a balance of Fe and unavoidable impurities and forming an Al | 10-06-2011 |
20120085209 | CUTTING METHOD OF STEEL FOR MACHINE STRUCTURAL USE - The cutting method of steel for machine structural use includes: forming a mist by mixing a cutting fluid supplied at a supply rate of 0.01 ml/hour to 200 ml/hour and an oxidizing gas containing, by volume %, 21% to 50% of oxygen; and cutting the steel for machine structural use while the mist is blown on the cutting edge surface of a tool and the surface of the steel for machine structural use, wherein the steel for machine structural use includes, by mass %: C: 0.01% to 1.2%, Si: 0.005% to 3.0%, Mn: 0.05% to 3.0%, P: 0.001% to 0.2%, S: 0.001% to 0.35%, N: 0.002% to 0.035%, Al: 0.05% to 1.0%, and the balance consisting of Fe and inevitable impurities in which O is limited to 0.003% or less, and the amount of Al [Al %] and the amount of N [N %] satisfy [Al %]−(27/14)×[N %]≧0.05. | 04-12-2012 |
20130025747 | STEEL FOR INDUCTION HARDENING, ROUGHLY SHAPED MATERIAL FOR INDUCTION HARDENING, PRODUCING METHOD THEREOF, AND INDUCTION HARDENING STEEL PART - A steel for an induction hardening including, by mass %, C: more than 0.75% to 1.20%, Si: 0.002 to 3.00%, Mn: 0.20 to 2.00%, S: 0.002 to 0.100%, Al: more than 0.050% to 3.00%, P: limited to 0.050% or less, N: limited to 0.0200% or less, O: limited to: 0.0030% or less, and the balance composing of iron and unavoidable impurities, wherein an Al content and a N content satisfy, by mass %, Al−(27/14)×N>0.050%. | 01-31-2013 |
20130101457 | STEEL FOR MACHINE STRUCTURE EXHIBITING EXCELLENT MACHINABILITY - This steel for a machine structure contains, in mass %: C: 0.40% to less than 0.75%; Si: 0.01% to 3.0%; Mn: 0.1% to 1.8%; S: 0.001% to 0.1%; Al: more than 0.1% and not more than 1.0%; N: 0.001% to 0.02%; and P: limited to not more than 0.05%, with a balance including Fe and inevitable impurities, in which the steel satisfies 139.38 ≦214×[C]+30.6×[Si]+42.8×[Mn]−14.7×[Al]≦177 and 0.72≦[C]+1/7×[Si]+1/5×[Mn]<1.539. | 04-25-2013 |
20130213199 | METHOD OF CUTTING STEEL FOR MACHINE STRUCTURAL USE - In the method of cutting steel for machine structural use, steel for machine structural use, in which chemical components contain, by mass %, 0.01% to 1.2% of C, 0.005% to 3.0% of Si, 0.05% to 3.0% of Mn, 0.001% to 0.2% of P, 0.001% to 0.35% of S, 0.002% to 0.035% of N and 0.05% to 1.0% of Al, in a case in which [Al%] and [N%] represent the mass % of Al and N in the steel respectively, [Al%]−(27/14)×[N%]≧0.05% is satisfied, is the other elements are included as necessary, and a balance consisting of Fe and inevitable impurities, is used, and a cutting process is carried out on the steel for machine structural use using water-insoluble cutting oil in which the amount of dissolved oxygen is 4 volume % to 16 volume %. | 08-22-2013 |